University of College Cork-National University of Ireland Cork, Ireland
Professor, Department of Oncology Director and Professor Gerald O’Sullivan Chair, Cancer Research Adjunct Associate Professor of Medical Oncology, Johns Hopkins University
Investigating new and innovative biomarkers to support more individualized treatment plans for triple-negative breast cancer patients.
Immune checkpoint proteins are key players in preventing the immune system from attacking cells indiscriminately. Some cancers can evade an immune response by simulating these proteins, which in turn decreases anti-tumor immunity. Immunotherapy agents can block these immune checkpoint proteins and demonstrate impressive tumor shrinkage and long-term survival in some patients with select cancers such as advanced triple-negative breast cancer (TNBC). More recent clinical trials have demonstrated significant clinical benefit adding the immune checkpoint inhibitor pembrolizumab to neoadjuvant (pre-surgical) chemotherapy in early-stage TNBC. While this combination has become standard of care for these patients, not all patients benefit. Dr. Connolly is focused on identifying biomarkers that can help determine which patients would benefit from this combination treatment, ensuring a more personalized treatment approach, minimizing treatment-related side effects while maintaining efficacy.
To undertake this project, Dr. Connolly and her team have formed a new collaborative cancer team in University College Cork (Ireland) comprised of laboratory and clinical scientists, postdoctoral researchers, research nursing, and pathology experts and has established collaborations across the Irish scientific research community. The team has made significant progress in immune and microbial analysis of bio-banked breast tumor samples from patients with TNBC treated with neoadjuvant chemotherapy with or without pembrolizumab. Dr. Connolly’s overarching goal is to ensure that patients with TNBC have a personalized approach to breast cancer treatment, tailoring the right treatment for the right patient.
Dr. Connolly and her colleagues will complete the immune and microbial sample analysis and correlate biomarkers in the samples with clinical outcomes, including pathologic complete response and survival. The team is also in the process of opening a new prospective clinical trial protocol for patients with TNBC at Cork University Hospital, Ireland. The study will include the collection of samples pre- and post-neoadjuvant chemotherapy with and without pembrolizumab and will evaluate a comprehensive range of breast cancer biomarkers relevant to treatment response.
Roisin Connolly, MD is the Professor Gerald O’Sullivan Chair in Cancer Research at University of College Cork (UCC) and Cork University Hospital (CUH). She is also the Director of Cancer Research at UCC, a Principal Investigator with Cancer Trials Cork at CUH, and assumed the role of Co-Chair of the Cancer Trials Ireland Breast Disease Specific Group in 2020. Prior to this, she was an associate professor of Oncology (Women’s Malignancy Program) from 2011, and Co-Director of the Developmental Therapeutics Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. Dr. Connolly graduated with a “first-class honors” medical degree from Trinity College, Dublin in 2001 and completed medical oncology fellowship training in both Ireland and at Johns Hopkins.
As a medical oncologist and clinical investigator, Dr. Connolly has significant expertise in the development of biomarkers of response to anti-cancer therapies, and the design and conduct of clinical trials that test investigational new drugs in the treatment of patients with both early- and late-stage cancers. In fact, she has led numerous multicenter clinical trials in collaboration with the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute (NCI), the Translational Breast Cancer Research Consortium (TBCRC), and the Eastern Co-operative Oncology Group (ECOG-ACRIN) in the U.S. Dr. Connolly is Study Chair for the international phase III ECOG-ACRIN study and received the prestigious ECOG-ACRIN Young Investigator Award in 2019 for excellence in clinical investigation. She has also recently received an Irish Cancer Society grant to support a Women’s Cancer Survivorship Clinic in Cork, in collaboration with national and international teams.
Dr. Connolly has been awarded a Health Research Board grant to support the UCC Cancer Trials Group, a network of clinical trials units in the South of Ireland. Through this funding, she will lead the expansion and availability of innovative clinical trials and investigator-led clinical projects to reach patients in this region. In addition, this award will focus on training the next generation of cancer researchers and research staff. In 2022, she received dedicated funding for clinical research fellowships from Breakthrough Cancer Research.
2022
Please remember BCRF in your will planning. Learn More
2X MATCH
Today, your gift is DOUBLED for 2X the impact on lifesaving research.
